Unmasking BDUC: Johanna Gebhart’s Call for Change at EHC 2025
Johanna Gebhart, Associate Professor and Haemostasis Expert at the Medical University of Vienna, shared a post by Wolfgang Miesbach on LinkedIn:
”It was a real pleasure to present our work on Bleeding Disorder of Unknown Cause (BDUC) at EHC 2025 in Vienna.
BDUC remains a challenging and often overlooked condition – yet it affects many patients with mild to moderate bleeding where no clear cause is found. Advancing research in this field is essential to ensure these patients receive the attention and care they deserve.
Many thanks to Wolfgang Miesbach for acknowledging our work and to the European Haemophilia Consortium for providing such an inspiring platform to share and discuss these important topics.”
Quoting Wolfgang Miesbach’s post:
”Great Research at EHC 2025. The great presentation by Johanna Gebhart from the Medical University of Vienna at this year’s EHC Conference in Vienna, focused on “BDUC: a new group that deserves attention”.
Dr. Gebhart’s work on Bleeding Disorder of Unknown Cause (BDUC) may transform our understanding of this challenging diagnostic and treatment category. Her research reveals that BDUC affects up to 60% of patients with mild-to moderate bleeding disorders where no underlying cause:
– BDUC patients show bleeding phenotypes indistinguishable from other mild bleeding disorders
– Contributing factors include blood group O, increased tissue factor pathway inhibitor, activated protein C, and decreased vitamin C levels
– BDUC significantly impacts health-related quality of life despite “normal” lab results
– Treatment options remain limited with few evidence-based therapies available
As the Principal Investigator of the Vienna Bleeding Biobank (VIBB), Dr. Gebhart is pioneering research into the pathophysiology of these previously overlooked bleeding tendencies. Her work emphasizes that BDUC patients deserve the same attention and specialized care as those with well-defined bleeding disorders.”
Stay updated with Hemostasis Today.
-
Oct 28, 2025, 14:27Maha Othman on 10-Year Anniversary of the CanVECTOR Research Network!
-
Oct 28, 2025, 14:00Claudio Laudani on PCSK9 Association with Increased Platelet Reactivity: A Pooled Analysis
-
Oct 28, 2025, 13:31Laurent Bertoletti Invites You to The INNOVTE and GITA Joined Meeting on Hormones and Thrombosis
-
Oct 28, 2025, 12:28Courtney Lawrence: Honored to Team Up with BET on Blood at AABB 2025
-
Oct 27, 2025, 19:45Benedikt Lorenz on Liver Failure and Coagulation – Myths, Traps, and Bad Habits
-
Oct 28, 2025, 13:09Gregory Piazza on CORONA-VTE Network Analysis
-
Oct 27, 2025, 18:42Khaled Musallam Shares BEYOND Trial Phase 2 Insights on Luspatercept Use in NTD β-Thalassaemia
-
Oct 27, 2025, 13:30Fabrice Cognasse: When Platelets Meet Artificial Intelligence!
-
Oct 27, 2025, 13:00Hossam El Benawi Shares Multi Site LVT Study from Mayo Clinic
-
Oct 27, 2025, 09:16Prof. Frank Leebeek: About 20 % of People with Von Willebrand's Disease Have Something Strange Going On
-
Oct 27, 2025, 09:19Mitra Najafi: Digital Storage Device - Specifically Designed and Developed to Store and Preserve PRP
-
Oct 25, 2025, 07:42Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 27, 2025, 15:10David McIntosh: Making Measurable Progress – Towards a World in Which No-one Ever Dies from Lack of a Vital Plasma-Derived Medicine
-
Oct 27, 2025, 13:18Stroke Foundation Welcomes Jacqui McCallum as the New Executive Director
-
Oct 27, 2025, 12:54Guillermo Lahera Forteza on Stroke and Mental Health
-
Oct 27, 2025, 12:37Joshua Ngimbwa Recognised as the Best Male Junior Investigator Awardee at the Tanzania Health Summit
-
Oct 27, 2025, 09:22Dr. Zsuzsa Bagoly Presents an Overview with Famous People that Suffered from a Stroke